Stock Track | Personalis Soars 5.34% Pre-market on Medicare Coverage for Breast Cancer Test

Stock Track11-10

Shares of Personalis (PSNL) surged 5.34% in pre-market trading on Monday, following a significant announcement regarding Medicare coverage for one of its key products. The precision oncology company's stock price movement reflects investor optimism about the potential impact of this development on the company's future prospects.

Personalis revealed that its ultrasensitive Minimal Residual Disease (MRD) test for breast cancer has received Medicare coverage. This breakthrough could substantially expand the accessibility of the test to a broader patient population, potentially driving increased adoption and revenue for the company. The MRD test is designed to detect residual cancer cells after treatment, which is crucial for monitoring and managing breast cancer patients.

The Medicare coverage decision is a significant milestone for Personalis, as it validates the clinical utility of their test and could pave the way for wider insurance coverage. This development may not only boost the company's market position in the competitive oncology diagnostics field but also contribute to improved patient care in breast cancer management. Investors appear to be pricing in the potential for increased test volumes and revenue growth, as reflected in the pre-market stock price surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161970687?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161970687","market":"hk","top_or_hot":-1,"title":"Stock Track | Personalis Soars 5.34% Pre-market on Medicare Coverage for Breast Cancer Test","media":"Stock Track","content":"<p>Shares of Personalis (PSNL) surged 5.34% in pre-market trading on Monday, following a significant announcement regarding Medicare coverage for one of its key products. The precision oncology company's stock price movement reflects investor optimism about the potential impact of this development on the company's future prospects.</p>\n\n<p>Personalis revealed that its ultrasensitive Minimal Residual Disease (MRD) test for breast cancer has received Medicare coverage. This breakthrough could substantially expand the accessibility of the test to a broader patient population, potentially driving increased adoption and revenue for the company. The MRD test is designed to detect residual cancer cells after treatment, which is crucial for monitoring and managing breast cancer patients.</p>\n\n<p>The Medicare coverage decision is a significant milestone for Personalis, as it validates the clinical utility of their test and could pave the way for wider insurance coverage. This development may not only boost the company's market position in the competitive oncology diagnostics field but also contribute to improved patient care in breast cancer management. Investors appear to be pricing in the potential for increased test volumes and revenue growth, as reflected in the pre-market stock price surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Personalis Soars 5.34% Pre-market on Medicare Coverage for Breast Cancer Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Personalis Soars 5.34% Pre-market on Medicare Coverage for Breast Cancer Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-10 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Personalis (PSNL) surged 5.34% in pre-market trading on Monday, following a significant announcement regarding Medicare coverage for one of its key products. The precision oncology company's stock price movement reflects investor optimism about the potential impact of this development on the company's future prospects.</p>\n\n<p>Personalis revealed that its ultrasensitive Minimal Residual Disease (MRD) test for breast cancer has received Medicare coverage. This breakthrough could substantially expand the accessibility of the test to a broader patient population, potentially driving increased adoption and revenue for the company. The MRD test is designed to detect residual cancer cells after treatment, which is crucial for monitoring and managing breast cancer patients.</p>\n\n<p>The Medicare coverage decision is a significant milestone for Personalis, as it validates the clinical utility of their test and could pave the way for wider insurance coverage. This development may not only boost the company's market position in the competitive oncology diagnostics field but also contribute to improved patient care in breast cancer management. Investors appear to be pricing in the potential for increased test volumes and revenue growth, as reflected in the pre-market stock price surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSNL","symbol_name":"Personalis","start_time":0,"source_url":"","article_id":"1161970687","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161970687","pubTimestamp":1762784063,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Personalis (PSNL) surged 5.34% in pre-market trading on Monday, following a significant announcement regarding Medicare coverage for one of its key products. The precision oncology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PSNL":"Personalis"},"translate_title":"个股追踪|Personalis因乳腺癌检测医保覆盖盘前飙升5.34%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSNL":1},"content_text":"Shares of Personalis (PSNL) surged 5.34% in pre-market trading on Monday, following a significant announcement regarding Medicare coverage for one of its key products. The precision oncology company's stock price movement reflects investor optimism about the potential impact of this development on the company's future prospects.\nPersonalis revealed that its ultrasensitive Minimal Residual Disease (MRD) test for breast cancer has received Medicare coverage. This breakthrough could substantially expand the accessibility of the test to a broader patient population, potentially driving increased adoption and revenue for the company. The MRD test is designed to detect residual cancer cells after treatment, which is crucial for monitoring and managing breast cancer patients.\nThe Medicare coverage decision is a significant milestone for Personalis, as it validates the clinical utility of their test and could pave the way for wider insurance coverage. This development may not only boost the company's market position in the competitive oncology diagnostics field but also contribute to improved patient care in breast cancer management. Investors appear to be pricing in the potential for increased test volumes and revenue growth, as reflected in the pre-market stock price surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161970687","isCrawlerRequest":true}